Erika Hamilton, MD, FASCO

Theresa & the other #clinicaltrial patient volunteers are the heroes of #oncology, these brave 👨‍👩‍👧‍👦 make every drug advance possible. I'm lucky to be Theresa's doctor and I LOVE celebrating these milestones in @SarahCannonDocs clinic, just motivates us to go further faster! – at Alabama, USA

Fantastic data by @drsarahsam in #BRIDGET showing the activity of #tucatinib in pts with 🧠 mets....used in combo w/ standard therapies..building upon what we saw in HER2CLIMB. ⬆️ unmet need! #ESMO26 #ESMOAmbassadors @OncoAlert

Wait....in important #ESMO26 musings while desperately trying to get something to eat or drink at some point today..... Does gum contain plastic?

#FOURLIGHT1 CDK4 atirmociclib Fulv + atirmo vs TPC (fulvestrant or exe/evero) post ET+ CDK4/6 in ER+ #bcsm PFS improved 6.6 to 9.4 mos, HR 0.60 #ESMO26 #ESMOAmbassadors @OncoAlert **1st line trial and curative trials coming!***

#FINER fulvestrant +/- ipatasertib (AKTi) 45% of pts were pathway altered PFS lengthened in ITT HR 0.68 and AKT altered cohorts HR 0.55 93% diarrhea, pretty high G2/3 rates #ESMO26 #ESMOAmbassadors

KNB49 HR+ adv #bcsm with PDL+, chemo +/- pembro once chemo appropriate Only 19.4% of pts eligible (majority weren't PDL1+) ~79% of + were CPS 1-9 PFS improved 6 to 6.7 mo, but tail of curve much better at 24 mo 4.3 vs. 14% remaining on PFS CPS of 19 4.4 vs. 7.5 mos #ESMO26

#BSTRONGER 🤯 that 95.1% of pts w/ stage I-III TNBC had ctDNA at baseline!!! Wow. By C3, >80% pts had cleared ctDNA in response to chemo Molecular response was associated with tumor burden: 100% stage I 85% stage II 44% stage III, cleared #ESMO26 #ESMOAmbassadors @OncoAlert

Sandra Franco brings up such an important point 💡 in her discussion at #ESMO26. Personally, I feel like our QOL metrics are falling short. Too often we hear "QOL was maintained" and missing so much. These quantitative scales ⚖️ do these qualitative 💔 AEs disjustice. #bcsm

Ok, #bcsm, what do we make of exemestane looking worse than anastrazole by 4.9% in GIM3 FATA? Fluke? Otherwise, no difference between upfront or switch strategies. #ESMO26 #ESMOAmbassadors

#PANKUBreast01 Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC 🔹mPFS: 4.0 vs. 8.1 mo, HR 0.41 🔹 ORR: 20% vs 40% 🔹 DoR: 4.2 vs. 6.9 mo 🔹 ILD: only 1.1% & all grade 1/2 #ESMO26 #ESMOAmbassadors

NATALEE @ 6 yrs: NSAI +/- ribo in HR+ early #bcsm: • 6-year OS: 91.9% vs 89.7%, 🔼 2.1%, HR 0.81 (95% CI 0.66–0.99); nominal 1-sided P=0.019 • 6-year iDFS: 83.2% vs 77.9%, 🔼 5.3% HR 0.74 (95% CI 0.65–0.85) #ESMO25 #ESMOAmbassadors @OncoAlert

#B42 extended endocrine therapy, addntl 5 years of AI after 5 yrs of ET @15 yr f/u improvement in DFS w/ extended therapy is 5.1% Majority of difference is in distant events No significant diff in fractures or thrombotic events #ESMO26 #ESMOAmbassadors

Fantastic summary slide of metastatic #bcsm #ADC landscape by @BarbaraPistill2 in her #ESMO26 discussion #ESMOAmbassadors @OncoAlert What do we need next??? 📍novel payloads 📍novel targets 📍data on sequencing

#APEXBr01: Rolditamig deuderuxtecan - ECD2 and ECD4 HER-2 ADC, DAR ~ 6 1st line cytotoxic for HER-2 low either TNBC or HR+, all PDL-1 neg PFS in all HER-2 low pts: improved from 5.5 to 16.4 (HR 0.29) OS trend HR 0.44 Heme tox most common, ILD 2.2% (no deaths) #ESMO26

Trastuzumab rezetecan in #HER2 low #bcsm (HORIZON-Br06) vs. TPC chemo 📍HER-2 low (TNBC or HR+) w/ up to 1 prior chemo 👏 PFS improved 6.8 to 16.6 mo (HR 0.25) in chemo naive 🟰 PFS ⬆️ in HR+ & HR- & across subgroups Neutropenia most common AE #ESMO26 #ESMOAmbassadors

#ESMO26 is upon us, start your meeting with the #OpeningSession! @myESMO